Guardant Health (GH) Looks Good: Stock Adds 6% in Session

In this article:

Guardant Health, Inc. GH was a big mover last session, as the company saw its shares rise 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $64.07–$78.27 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen two positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Guardant Health. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Guardant Health currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Guardant Health, Inc. Price

Guardant Health, Inc. Price
Guardant Health, Inc. Price

Guardant Health, Inc. price | Guardant Health, Inc. Quote

A better-ranked stock in the Medical - Biomedical and Genetics industry is Anika Therapeutics Inc. ANIK, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is GH going up? Or down? Predict to see what others think: Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report
 
Guardant Health, Inc. (GH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement